Pregabalin Capsule
Product Images NDC 70518-2525

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-2525). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin 75mg 70518 2525 00

This is a description of a medication named Pregabalin. The medication comes in a bottle with a National Drug Code number of 70518-2525-00 and contains 90 capsules of 75 milligrams each. The medication was manufactured by Novadoz Pharmaceuticals LLC in New Jersey, US. The lot number and expiration date are not available. The source NDC number is 72205-0013-90. The medication should be kept out of reach of children and stored in a cool and dry place at a temperature between 20-26°C (63-77°F), with excursions between 15-30°C (59-86°F). It is for Rx only and has been repackaged by RemedyRepack Inc. in Indiana, PA. *

FDA Label Image

Equation (Pregabain Gault Equation)

This is a formula for calculating creatinine clearance in patients. It takes into account the patient's age, weight, and serum creatinine levels. If the patient is female, the result is multiplied by 0.85.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

FDA Label Image

Fig-02 (Pregabalin Figure 02)

This is a graph showing the percentage of patients who improved after taking Pregabalin 100 mg three times a day compared to a placebo. The improvement in pain from baseline is also displayed in percentages ranging from 10 to 100.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

FDA Label Image

Fig-04 (Pregabalin Figure 04)

This appears to be a graph or chart showing the percentage of patients who improved based on different levels of pain relief from baseline. The x-axis measures different improvement levels (10%, 20%, 30%, etc.) while the y-axis measures the percentage of patients who reported improvement. Three treatments are being compared: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and a placebo.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

The text shows a table that displays the percentage of patients who saw an improvement in pain from baseline when taking pregabalin at varying doses as compared to placebo. The table also includes the percent improvement in pain from baseline at different levels.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

The text appears to be a table showing responder rates (%) from a study or studies (E1 and E3) with different dosages (50mg/day, 150mg/day, 300mg/day, 600mg/day) of a drug compared to a placebo. The data is presented for different dosing frequencies (BID and TID). There is a statistically significant difference in response rates between the drug and placebo at certain dosages. There is one cell with the value of 14%, and another cell with the value of 15% that doesn't seem to correspond with any particular dosage or frequency. However, without additional context, it is difficult to determine the purpose or significance of this table.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

This is a chart displaying results of a study, with values and p-values for different doses. The doses are listed in mg/day, with a placebo listed at 0 mg/day. There are different groups indicated by names such as Stukly E1BID, etc. The chart shows values for each group at different doses, with significant p-values indicated.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

This appears to be a chart showing the percentage of patients who experienced improvements in pain from baseline after taking different doses of Pregabalin or placebo. The x-axis shows the percentage improvement in pain while the y-axis shows the percentage of patients who experienced that level of improvement. There are four lines on the chart, representing different daily doses of Pregabalin (600 mg, 450 mg, and 300 mg) and a placebo group. The chart shows that a higher percentage of patients experienced improvement in pain with increasing doses of Pregabalin compared to the placebo group.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

FDA Label Image

Fig-11 (Pregabalin Figure 11)

The text is a graph showing the percent of subjects who improved from baseline to week 12 with the drug Pregabalin compared to a placebo. The graph shows values at various intervals from 0 to 100.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

This table shows the percentage of subjects who showed improvement during a 16-week treatment period with either Pregabalin or Placebo, using BOCF B as the measure. The percentages range from 0 up to 100 with increments of 10, and the text indicates the number of subjects who demonstrated improvement at or above each increment.*

FDA Label Image

Str (Pregabalin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.